Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Anusak Laowilas/NurPhoto via Getty Images

The deadly coronavirus has not yet sufficiently spread internationally to designate the outbreak as a global health emergency, the World Health Organization announced Thursday.

Why it matters: Some say the lack of a declaration of a Public Health Emergency of International Concern (PHEIC) could lessen international focus and funding needed to address a potential threat, but others worry such a declaration could limit the travel and trade important to many people's livelihoods.

"Make no mistake. This is an emergency in China, but it has not yet become a global health emergency. WHO's risk assessment is that the outbreak is a very high risk in China, and a high risk regionally and globally."
— Tedros Adhanom Ghebreyesus, WHO director-general, said at a news conference

The latest: China's National Health Commission reported Thursday night that the country has seen 835 confirmed cases and 25 deaths. The CDC also reports one case in the U.S.

  • WHO says based on its regular updates from China, it appears the virus can be transmitted between humans, but it's still uncertain how readily infectious it is, as most of the cases have been in family groups or between a patient and a health worker.
  • Most deaths so far have occurred in people who have underlying health conditions, like hypertension or diabetes.

What they're saying: The WHO should have issued a PHEIC to better mobilize resources, and China's efforts to isolate cities with the highest infections could backfire, according to Lawrence Gostin, faculty director of Georgetown University's O’Neill Institute for National and Global Health Law.

  • Recent moves by China to suspend travel from certain cities could lead to citizen panic and distrust for their government officials, Gostin tells Axios.
  • "How do you enforce a lockdown of a city the size of New York or London without a massive violation of human rights and provoking fear?"

Plus, curbing Lunar New Year festivities is also expected to have an economic impact. Already, there are some signs this outbreak has caused financial damage, as the prices of some Wuhan-based stocks dropped and traders are keeping an eye on other markets.

Meanwhile, two U.S. public health officials and a scientist from Penn State University College of Medicine published a viewpoint piece Thursday in the journal JAMA. Per their piece...

  • Experience from the prior two coronavirus outbreaks (SARS and MERS) that "emerged from animal reservoirs to cause global epidemics with alarming morbidity and mortality" is now informing current response activities and helped initiate vaccine development.
  • Diagnostics are being "rapidly adapted" to include this new virus to improve the identification and isolation of infections.
  • Broad-spectrum antivirals that showed some promise against MERS — such as remdesivir, lopinavir and ritonavir combo, and interferon beta — are being assessed for 2019-nCoV.
  • Vaccines are being developed, including one by the National Institute of Allergy and Infectious Diseases using the faster mRNA vaccine technology.

The bottom line: "The emergence of yet another outbreak of human disease caused by a pathogen from a viral family formerly thought to be relatively benign underscores the perpetual challenge of emerging infectious diseases and the importance of sustained preparedness," they write in JAMA.

Editor's note: This story updates the number of coronavirus cases and deaths confirmed by China's National Health Commission.

Go deeper:

Go deeper

Updated 21 mins ago - Politics & Policy

Omicron dashboard

Illustration: Shoshana Gordon/Axios

  1. Health: Concerns grow over CDC's isolation guidelines — Experts warn of more COVID-19 variants after Omicron.
  2. Vaccines: America's vaccination drive runs out of gas — Puerto Rico expands booster shot requirements.
  3. Politics: Joint Chiefs chair Gen. Mark Milley tests positive for COVID-19 — Vivek Murthy calls SCOTUS vaccine mandate block "a setback for public health."
  4. Economy: Report: World's 10 richest men doubled wealth during pandemicAmerica's labor shortage is bigger than the pandemic.
  5. States: America struggles to keep schools open — Youngkin ends mandates for masks in schools and COVID vaccinations for state workers.
  6. World: Greece imposes vaccine mandate for people 60 and older — French parliament passes COVID vaccine passport legislation.
  7. Variant tracker

Joint Chiefs chair Gen. Mark Milley tests positive for COVID-19

Photo: Olivier Douliery - Pool/Getty Images

Mark Milley, chairman of the Joint Chiefs of Staff, tested positive for COVID-19 on Sunday.

State of play: Joint Staff spokesperson Col. Dave Butler said in a statement that Milley — who is fully vaccinated and has received a booster shot — is experiencing "very minor symptoms" and is "working remotely and isolating himself."

Momentum builds to ban lawmakers from trading stocks

Illustration: Sarah Grillo/Axios

Some progressive Democrats and MAGA Republicans are uniting on a proposal to ban sitting lawmakers from trading individual stocks, although it's unlikely that leadership will bring the bill up for a vote.

Why it matters: Members of Congress have great power to move stock prices, and great financial incentives to do so.